Adicet Bio

Adicet has no product revenue and is funding early clinical programs. Outcomes for autoimmune CAR‑T remain uncertain; durability, relapse rates, manufacturing reproducibility, and real‑world safety in broader populations are not yet known.

While the company guided to a mid‑2026 update in LN/SLE, an FDA meeting in Q2 2026, and a potential pivotal start in 2H 2026, timelines and probability of technical and regulatory success are inherently volatile. This profile contrasts with the steady, recurring cash flows we target.